Abstract
Metabolic regulation is considered to be one of the key hallmarks of cancer. Due to its continuous proliferation and high energy demands, cancer cells undertake increased glucose uptake as proposed by Otto Warburg, resulting in the production of enough amount of energy for their replication and survival. Totally different from the normal cell metabolism, even at aerobic conditions, cancer cells undergo glycolysis rather than oxidative phosphorylation. These glycolytic events in cancer cells elevate the expression of enzymes responsible for glucose metabolism such as hexokinase, pyruvate kinase, and lactate dehydrogenase-A. In addition, increased glucose metabolism in cancer cells leads to the formation of necessary amino acids, lipids, purines, and pyrimidine via the inter-branching biosynthetic pathways such as pentose phosphate pathway, serine biosynthesis, and glutaminolysis. Although blood cancer cells have the same way of regulating their metabolism for the survival, carbohydrate metabolism relatively is known to have very less role in the metabolic regulation in blood tumors. Lipid metabolism via the STAT-3 pathways plays a crucial role in blood tumor metabolism via oxidative phosphorylation to meet their energy demands. A deep understanding of metabolic regulation in cancer cells can pave a novel path for finding specific targets and drugs that can target the cancer cell metabolism.
Keywords
- Solid tumor
- Nonsolid tumor
- Cancer metabolism
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Adekola KUA et al (2015) Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin. Leuk Lymphoma 56:450
Beloueche-Babari M et al (2017) MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy. Cancer Res 77:5913
Bentley DP et al (2000) The apoptotic pathway: a target for therapy in chronic lymphocytic leukemia. Hematol Oncol 18:87
Bhatt AP et al (2012) Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma. In: Proc Natl Acad Sci U S A, vol 109, p 11818
Bhutia YD et al (2016) Glutamine transporters in mammalian cells and their functions in physiology and cancer. Biochim Biophys Acta 1863(10):2531–2539
Bilban M et al (2006) Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. Leukemia 20:1080
Chiorazzi N et al (2007) Cell proliferation and death: Forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 20(3):399–413
Cho ES et al (2018) The pentose phosphate pathway as a potential target for cancer therapy. In: Biomol Ther (Seoul), vol 26, p 29
Clayton DA et al (1967) Circular dimer and catenate forms of mitochondrial DNA in human leukaemic leucocytes. Nature 216:652
Combs JA et al (2019) The non-essential amino acid cysteine becomes essential for tumor proliferation and survival. In: Cancers, vol 11. https://doi.org/10.3390/cancers11050678
Daniels TF et al (2009) Lipoproteins, cholesterol homeostasis and cardiac health. Int J Biol Sci 5(5):474–488
Davis SR et al (2004) Tracer-derived total and folate-dependent homocysteine remethylation and synthesis rates in humans indicate that serine is the main one-carbon donor. Am J Physiol Endocrinol Metab 286:E272
Denko NC (2008) Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 8(9):705–713
Flavin R et al (2010) Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol 6:551
Garcia-Ruiz C et al (2012) Statins and protein prenylation in cancer cell biology and therapy. Anti Cancer Agents Med Chem 12:303
Hatzivassiliou G et al (2005) ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8:311
Jitschin R et al (2014) Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia. Blood 123:2663
Kim TM et al (2013) Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer 119:1195
Kitada S et al (2002) Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 21:3459
Koppenol WH et al (2011) Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer 11(5):325–337
Krzeslak A et al (2012) Expression of GLUT1 and GLUT3 glucose transporters in endometrial and breast cancers. Pathol Oncol Res 18:721
Kumar D et al (2018) Cancer-associated fibroblasts drive glycolysis in a targetable signaling loop implicated in head and neck squamous cell carcinoma progression. Cancer Res 78:3769
Lien EC et al (2016) Metabolic reprogramming by the PI3K-Akt-mTOR pathway in cancer. Recent Results Cancer Res 207:39–72
Lisker A et al (1966) Abnormal carbohydrate metabolism in patients with malignant blood dyscrasias. Am J Med Sci 252(3):282–288
Lowndes SA et al (2008) Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res 14:7526
Maddocks ODK et al (2016) Serine metabolism supports the methionine cycle and DNA/RNA methylation through de novo ATP synthesis in cancer cells. Mol Cell 61:210
Mashima T et al (2009) De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 100:1369
Mehta MP et al (2009) Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung Cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 73:1069
Menendez J et al (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7:763
Nagai M et al (2012) The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells. Free Radic Biol Med 52:2142
Nayak MK et al (2018) Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis. Blood Adv 2:2029
Paquette J et al (2005) Rapid induction of the intrinsic apoptotic pathway by L-glutamine starvation. J Cell Physiol 202:912
Robey R et al (2009) Is Akt the “Warburg kinase”?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 19:25
Rozovski U et al (2014) Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123(24):3797–3802
Rozovski U et al (2015) Aberrant LPL expression, driven by STAT3, mediates free fatty acid metabolism in CLL cells. Mol Cancer Res 13(5):944–953
Ruby MA et al (2010) VLDL hydrolysis by LPL activates PPAR-α through generation of unbound fatty acids. J Lipid Res 51:2275
Santos C et al (2012) Lipid metabolism in cancer. FEBS J 279:2610
Shapiro GI et al (2005) Phase I trial of ARQ 501, an Activated Checkpoint Therapy (ACT) agent, in patients with advanced solid tumors. J Clin Oncol 23(16_suppl):3042
Shapovalov Y et al (2011) Mitochondrial dysfunction in cancer cells due to aberrant mitochondrial replication. J Biol Chem 286:22331
Simonnet H (2002) Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 23:759
Spaner DE et al (2013) PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia 27:1090
Stuart SD et al (2014) A strategically designed small molecule attacks alpha-ketoglutarate dehydrogenase in tumor cells through a redox process. Cancer Metab 2:4
Tili E et al (2012) The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood 120:2631
Till KJ et al (2015) Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells. In: J Immunol, vol 194, p 2439
Vogelstein B et al (2004) Cancer genes and the pathways they control. Nat Med 10:789
Warburg O (1956) On the origin of cancer cells. Science 123:309
Wise DR et al (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. In: Proc Natl Acad Sci U S A, vol 105, p 18782
Yang M et al (2016) Serine and one-carbon metabolism in cancer. Nat Rev Cancer 16:650
Yang L et al (2017) Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng 19:163
Yu M et al (2017) The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis. Oncotarget 8(26):43356–43367
Zhan T et al (2011) Silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins. J Cell Biochem 112:849
Zhou Q et al (2011) A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Investig New Drugs 29:340
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Raj, S., Chandel, V., Kumar, D. (2020). Cancer Cell Metabolism: Solid Tumor Versus Nonsolid Tumor. In: Kumar, D. (eds) Cancer Cell Metabolism: A Potential Target for Cancer Therapy. Springer, Singapore. https://doi.org/10.1007/978-981-15-1991-8_1
Download citation
DOI: https://doi.org/10.1007/978-981-15-1991-8_1
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-15-1990-1
Online ISBN: 978-981-15-1991-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)